ESSEX BIO-TECH (01061) announced that the company's indirect subsidiary, Guangdong Hanfeng Baisheng Pharmaceutical Co., Ltd., has obtained approval from the National Medical Products Administration for the registration and commercialization of multi-dose sodium hyaluronate eye drops (0.3%) within the People's Republic of China. The approved product is a multi-dose eye drop containing 0.3% (5ml:15mg) sodium hyaluronate, indicated for the treatment and relief of various endogenous eye diseases, exogenous eye diseases, and damage caused by surgery, medication, trauma, or contact lens wear.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments